This cohort study examines associations of glucagon-like peptide-1 receptor agonist (GLP-1 RA) use with cardiovascular and kidney outcomes across body mass index (BMI) categories in patients with type 2 diabetes. Here, GLP1R is linked to type 2 diabetes mellitus.